MGRX on Nasdaq

MANGOCEUTICALS, INC.

American misc health and allied services company based in Dallas. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with BioRestorative Therapies, Inc., NewGenIvf Group Ltd or Charming Medical Ltd, or pick any stock.

TickerMGRX on Nasdaq²
IndustryServices-Misc Health & Allied Services, NEC²
HeadquartersDallas, United States²
Incorporated inTX³
Business address15110 Dallas Pkwy, Suite 600, Dallas, Tx 75248³
Filer category, Emerging growth company³
Legal formCorporation²
LEI984500BKBD93A8A67E98²
StatusActive²
LEI statusLapsed (not renewed)²
Registered address15110 DALLAS PKWY STE 600, 75248 Dallas, United States²
Registered withCorporations Section (Texas Secretary of State), 0804264096²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

54.9%Gross margin⁴

-3954.3%Operating margin⁴

-4526.8%Net margin⁴

-26.0%Revenue growth, 2025⁴

-135.8%Return on equity⁴

Where the money goes

Where each dollar of revenue went, fiscal 2025

Cost of revenueOther costs

Cost of revenue12¢$54.4K
Other costs88¢$401.6K

Out of $456.0K in revenue.⁴ The company lost money this year.

Financial statements

Revenue⁵⁶⁴$456.0K in 2025+5001% since 2022

Gross profit⁵⁶⁴$250.4K in 2025+5063% since 2022

Operating income⁵⁶⁴-$18.0M in 2025+805% since 2022

Net income⁵⁶⁴-$20.6M in 2025+933% since 2022

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31
Revenues	$456.0K	$615.9K
Cost of revenues	$54.4K	$93.3K
Cost of revenues - related party	$151.2K	$142.6K
Gross profit	$250.4K	$380.0K
General and administrative expenses	$3.8M	$3.0M
Salary and benefits	$1.3M	$1.1M
Advertising and marketing	$822.9K	$1.5M
Investor relations	$1.6M	$453.7K
Stock based compensation	$10.8M	$2.4M
Total operating expenses	$18.3M	$8.4M
Loss from operations	-$18.0M	-$8.0M
Interest expense	$103.5K	$13.7K
Amortization of intangible assets	$1.1M	$721.5K
Impairment of license agreement	$1.2M
Loss from settlement	$125.6K
Loss from debt extinguishment - related parties	$19.4K
Total other (income) expense	$2.6M	$735.2K
Loss before income taxes	-$20.6M	-$8.7M
Net loss	-$20.6M	-$8.7M
Net loss attributed to non-controlling interest	-$461	-$1.1K
Net loss attributed to Mangoceuticals, Inc.	-$20.6M	-$8.7M
Basic loss per share	-$2.17	-$4.80
Diluted loss per share	-$2.17	-$4.80
Basic	10.1M shares	2.0M shares
Diluted	10.1M shares	2.0M shares
Preferred stock dividend requirements	$1.2M	$802.1K
Net loss attributed to Mangoceuticals, Inc. common stockholders	-$21.8M	-$9.5M

Total assets⁵⁶⁴$16.1M in 2025+1504% since 2022

Total liabilities⁵⁶⁴$890.6K in 2025+129% since 2022

Shareholders’ equity⁵⁶⁴$15.2M in 2025

Cash⁵⁶⁴$1.5M in 2025+118% since 2022

Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 6 quarters (quarterly), latest first.⁴

Period ending	2025-12-31	2025-05-31	2024-12-31	2024-10-31	2024-09-30
Cash and cash equivalents	$1.5M		$58.7K
Deposits	$33.9K		$16.9K
Due from related party	$20.1K
TOTAL CURRENT ASSETS	$1.5M		$75.6K
Property and equipment, net of accumulated depreciation of $1,012 and $2,256	$1.8K		$2.8K
Right of use - asset	$307.9K		$59.5K
Intangible assets - acquired patents and license, net of amortization and impairment	$14.2M		$15.2M
TOTAL NON-CURRENT ASSETS	$14.5M		$15.3M
TOTAL ASSETS	$16.1M		$15.4M
Accounts payable and accrued liabilities	$416.7K		$837.5K
Payroll tax liabilities	$9.4K
Notes payable			$150.0K
Right-of-use liability - operating lease	$307.8K		$65.0K
TOTAL CURRENT LIABILITIES	$890.6K		$1.4M
TOTAL LIABILITIES	$890.6K		$1.4M
Common stock (par value $0.0001), 200,000,000 shares authorized, of which 15,888,795 and 3,245,641 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	$1.6K		$325
Stock warrants	$324.3K		$324.3K
Subscription receivable			-$1.1M
Additional paid in capital	$55.5M		$34.8M
Accumulated deficit	-$40.6M		-$20.0M
Accumulated other comprehensive loss	-$2.8K		-$9.8K
TOTAL STOCKHOLDERS EQUITY	$15.2M		$13.9M
Non-controlling interest	-$1.5K		-$1.1K
TOTAL STOCKHOLDERS EQUITY	$15.2M		$13.9M
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	$16.1M		$15.4M
Accumulated depreciation	$1.0K		$2.3K
Preferred stock, par value	$0.00
Preferred stock, shares authorized	10.0M shares
Common stock, par value	$0.00		$0.00
Common stock, shares authorized	200.0M shares		200.0M shares
Common stock, shares issued	15.9M shares		3.2M shares	2.1M shares	32.0M shares
Common stock, shares outstanding	15.9M shares	93.7K shares	3.2M shares	2.1M shares	32.0M shares

Period ending	2025-12-31	2025-05-31	2024-12-31	2024-10-31	2024-09-30	2023-12-31
Cash and cash equivalents	$1.5M		$58.7K
Deposits	$33.9K		$16.9K
Due from related party	$20.1K
TOTAL CURRENT ASSETS	$1.5M		$75.6K
Property and equipment, net of accumulated depreciation of $1,012 and $2,256	$1.8K		$2.8K
Right of use - asset	$307.9K		$59.5K
Intangible assets - acquired patents and license, net of amortization and impairment	$14.2M		$15.2M
TOTAL NON-CURRENT ASSETS	$14.5M		$15.3M
TOTAL ASSETS	$16.1M		$15.4M
Accounts payable and accrued liabilities	$416.7K		$837.5K
Payroll tax liabilities	$9.4K
Notes payable			$150.0K
Right-of-use liability - operating lease	$307.8K		$65.0K
TOTAL CURRENT LIABILITIES	$890.6K		$1.4M
TOTAL LIABILITIES	$890.6K		$1.4M
Common stock (par value $0.0001), 200,000,000 shares authorized, of which 15,888,795 and 3,245,641 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	$1.6K		$325
Stock warrants	$324.3K		$324.3K
Subscription receivable			-$1.1M
Additional paid in capital	$55.5M		$34.8M
Accumulated deficit	-$40.6M		-$20.0M
Accumulated other comprehensive loss	-$2.8K		-$9.8K
TOTAL STOCKHOLDERS EQUITY	$15.2M		$13.9M
Non-controlling interest	-$1.5K		-$1.1K
TOTAL STOCKHOLDERS EQUITY	$15.2M		$13.9M			$774.8K
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	$16.1M		$15.4M
Accumulated depreciation	$1.0K		$2.3K
Preferred stock, par value	$0.00
Preferred stock, shares authorized	10.0M shares
Common stock, par value	$0.00		$0.00
Common stock, shares authorized	200.0M shares		200.0M shares
Common stock, shares issued	15.9M shares		3.2M shares	2.1M shares	32.0M shares
Common stock, shares outstanding	15.9M shares	93.7K shares	3.2M shares	2.1M shares	32.0M shares

Cash from operations⁵⁶⁴-$5.9M in 2025+334% since 2022

Capital spending⁵⁶$3.5K in 2023−92% since 2022

Free cash flow⁵⁶-$7.0M in 2023+404% since 2022

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁴

Period ending	2025-12-31	2024-12-31
Net loss	-$20.6M	-$8.7M
Depreciation	$1.0K	$9.9K
Issuance of common stock for services	$10.7M	$2.1M
Options vested for stock-based compensation	$1.2M	$248.7K
Loss on sale of assets		$18.4K
Amortization of intangible assets	$1.1M	$721.5K
Amortization of license agreement	$600.6K
Operating lease right of use asset	$68.5K	$59.8K
Inventory obsolescence		$18.5K
Loss from settlement	$125.6K
Loss from debt extinguishment related parties	$19.4K
Deposits	-$17.0K
Accounts payable and accrued liabilities	$55.7K	$696.7K
Accrued liabilities - related parties		-$63.7K
Operating lease right-of-use liabilities	-$74.0K	-$6.6K
Payroll tax liabilities	$9.4K
Other liabilities	-$216.4K	-$27.0K
NET CASH USED IN OPERATING ACTIVITIES	-$5.9M	-$4.9M
Sale of assets		$65.0K
NET CASH PROVIDED BY(USED IN) INVESTING ACTIVITIES		$65.0K
Proceeds from borrowings on notes payable	$500.0K	$150.0K
Proceeds from borrowings on notes payable - related parties	$175.0K
Proceeds from sales of common stock	$4.6M	$1.3M
Proceeds from sales of series B convertible preferred stock	$100.0K	$2.6M
Proceeds from exercise of warrants	$927.0K
Collection of subscriptions receivable	$1.1M
Repayment of borrowings on notes payable - related parties	-$206.5K
NET CASH PROVIDED BY FINANCING ACTIVITIES	$7.3M	$4.1M
End of period	$1.4M	-$670.5K
Effects of currency translation on cash and cash equivalents	$7.1K	-$9.8K
Right of use assets acquired under new operating leases	$316.9K
Issuance of common stock for license agreement	$2.0M
Issuance of common stock for patent acquisition		$1.3M
Issuance of Series C Convertible Preferred for patent acquisition		$14.2M
Issuance of common stock for payment of Preferred B dividend		$70.2K
Issuance of common stock for settlement of debt settlement	$590.0K
Issuance of common stock for settlement of note payable	$500.0K
Issuance of common stock for settlement of note payable - related parties	$150.0K
Issuance of common stock for conversion of Series B Convertible Preferred	$201	$1.1M
Issuance of common stock for cashless warrant exercise	$23

Compare MANGOCEUTICALS, INC. with another company

Leadership

Who has led MANGOCEUTICALS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

Jacob D. Cohen2023–now

President

Chief financial officer

Eugene M. Johnston2023–now

Chief operating officer

2025

Chief executive officerJacob D. Cohen Mar 20, 2023 to now⁹
PresidentAntonios Isaac Jan 21, 2025 to now¹⁰
PresidentJonathan Arango Mar 20, 2023 to Mar 20, 2023¹¹
Chief financial officerEugene M. Johnston Mar 20, 2023 to now¹²
Chief operating officerJonathan Arango Mar 20, 2023 to Mar 20, 2023¹¹
Chief operating officerAmanda Elizabeth Hammer May 4, 2023 to Jun 5, 2024¹³

Board members and other officers (5)

Board memberAntonios Isaac Jan 21, 2025 to now¹⁰
Board memberJacob D. Cohen Mar 20, 2023 to now⁹
Board memberJonathan Arango Mar 20, 2023 to Mar 20, 2023¹¹
Board memberKenny Myers Mar 20, 2023 to now¹⁴
Board memberLorraine Pamela D'Alessio Mar 20, 2023 to now¹⁵

Timeline

Mar 20, 2023New chief executive Jacob D. Cohen becomes CEO⁹
Oct 7, 2021Founded MANGOCEUTICALS, INC. is founded²

Filings

240 filings to the SEC since October 2021: 3 annual reports, 12 quarterly reports, 78 major events, 39 insider forms, 8 large holders, 2 private raises, 98 other. The latest 20:

Oct 9, 20268-K EDGAR
Oct 9, 2026424B5 EDGAR
Oct 6, 20264 EDGAR
Oct 6, 2026SCHEDULE 13D/A EDGAR
Oct 6, 20264 EDGAR
Oct 6, 20264 EDGAR
Oct 1, 20268-K EDGAR
Aug 21, 20268-K EDGAR
Aug 13, 202610-Q EDGAR
Aug 13, 2026425 EDGAR
Aug 6, 2026425 EDGAR
Aug 4, 2026425 EDGAR
Aug 4, 20268-K EDGAR
Jul 30, 2026425 EDGAR
Jul 30, 2026425 EDGAR
Jul 30, 20268-K EDGAR
Jul 10, 2026S-8 EDGAR
Jul 2, 20268-K EDGAR
May 19, 202610-Q EDGAR
May 15, 2026NT 10-Q EDGAR

The 240 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

7 open-market trades by officers, directors and large owners since October 2021: 1 buys and 6 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Dec 15, 2025	JOHNSTON EUGENE MCFO	Sale	3,333	$1.17	$3.9K	Form 4
Dec 9, 2025	JOHNSTON EUGENE MCFO	Sale	5,000	$1.20	$6.0K	Form 4
Dec 5, 2025	JOHNSTON EUGENE MCFO	Sale	10,000	$1.13	$11.3K	Form 4
Nov 19, 2025	Hamilton Alex P.Director	Sale	125,000	$1.22	$152.5K	Form 4
Jun 26, 2024	Hamilton Alex P.Director	Sale	108,426	$0.32	$34.7K	Form 4
Jun 25, 2024	Hamilton Alex P.Director	Sale	16,574	$0.31	$5.1K	Form 4
Apr 10, 2023	Tiger Cub Trust10% owner	Buy	275,000	$1.00	$275.0K	Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Jacob D. CohenSCHEDULE 13D/A, 7 filings May 3, 2023 to Oct 6, 2026¹⁶
GREENFIELD INVESTMENTS LTD.SCHEDULE 13G, 1 filing Jan 22, 2025¹⁷

Money raised

Private offerings the company reported to the SEC on Form D.

Aug 16, 2022Raised $1.5 million in a private offering of equity Form D: $2 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Citadel Advisors LLC	338,964	$128.8K	0.0%	New
XTX Topco Ltd	186,256	$70.8K	0.0%	+173,114
Geode Capital Management, LLC	156,243	$59.4K	0.0%	−38,239
Ikarian Capital, LLC	138,146	$52.5K	0.0%	No change
Vanguard Capital Management LLC	123,041	$46.8K	0.0%	No change
Vanguard Fiduciary Trust Co	57,163	$21.7K	0.0%	No change
Boothbay Fund Management, LLC	38,441	$14.6K	0.0%	No change
Northern Trust Corp	37,579	$14.3K	0.0%	No change
Ackerman Capital Advisors, LLC	34,500	$13.1K	0.0%	No change
ACT Advisors, LLC.	26,863	$10.2K	0.0%	New
Goldman Sachs Group Inc	11,589	$4.4K	0.0%	−168
Csenge Advisory Group	10,000	$3.8K	0.0%	No change
Ameriflex Group, Inc.	2,885	$1.1K	0.0%	New
Fortitude Family Office, LLC	1,343	$510	0.0%	No change
Morgan Stanley	1,000	$380	0.0%	No change
Tower Research Capital LLC (TRC)	783	$298	0.0%	−2
Hrt Financial LP	36,003	$13	0.0%	New
Barclays PLC	5	$2	0.0%	New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARMANGOCEUTICALS, INC. filings on SEC EDGAR
2
GLEIFMANGOCEUTICALS, INC. LEI record (984500BKBD93A8A67E98)
3
SEC EDGARMANGOCEUTICALS, INC. filings on SEC EDGAR
4
SEC EDGARMANGOCEUTICALS, INC. 10-K for fiscal 2025
5
SEC EDGARMANGOCEUTICALS, INC. 10-K for fiscal 2022
6
SEC EDGARMANGOCEUTICALS, INC. 10-K for fiscal 2023
7
SEC EDGARMANGOCEUTICALS, INC. 10-Q for fiscal 2026
8
SEC EDGARMANGOCEUTICALS, INC. 10-Q for fiscal 2026
9
SEC EDGARJacob D. Cohen, Chief executive officer
10
SEC EDGARAntonios Isaac, President
11
SEC EDGARJonathan Arango, President
12
SEC EDGAREugene M. Johnston, Chief financial officer
13
SEC EDGARAmanda Elizabeth Hammer, Chief operating officer
14
SEC EDGARKenny Myers, Board member
15
SEC EDGARLorraine Pamela D'Alessio, Board member
16
SEC EDGARJacob D. Cohen SCHEDULE 13D/A on MANGOCEUTICALS, INC.
17
SEC EDGARGREENFIELD INVESTMENTS LTD. SCHEDULE 13G on MANGOCEUTICALS, INC.